文献速递帕金森病与运动障碍

夜间皮下注射阿扑吗啡治疗帕金森病患者失眠的安全性及有效性(APOMORPHEE):一项多中心、随机、对照、双盲交叉研究

Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.
PubMed 文献 · Lancet Neurol · 2022-01-01

该研究在法国11个帕金森病与睡眠中心开展随机、多中心、双盲、安慰剂对照交叉试验,纳入46例伴中重度失眠的波动型帕金森病患者,比较夜间皮下阿扑吗啡输注与安慰剂的疗效与安全性。结果显示阿扑吗啡组PDSS评分改善显著优于安慰剂组,治疗效应为9.95(95%CI 0.88-19.03),p=0.041;不良事件发生率两组无显著差异。

要点

  • 夜间皮下阿扑吗啡输注较安慰剂显著改善帕金森病患者PDSS评分,治疗效应9.95(95%CI 0.88-19.03),p=0.041。
  • 阿扑吗啡组不良事件报告25例(54%),安慰剂组17例(37%),两组比较p=0.16,无显著差异。
  • 阿扑吗啡组头晕发生率高于安慰剂组(7例[15%] vs 0例),p=0.041。

核心结论

  • 夜间皮下阿扑吗啡输注可改善帕金森病患者的睡眠障碍,其PDSS评分变化差异显著优于安慰剂,总体安全性特征与既往帕金森病研究一致。
  • 作者认为该治疗可能有助于管理晚期帕金森病伴中重度失眠患者的睡眠障碍。

研究设计与样本

  • 研究为随机、多中心、双盲、安慰剂对照交叉试验,在法国11个帕金森病与睡眠中心开展。
  • 纳入年龄35-90岁、伴波动型帕金森病及中重度失眠(失眠严重程度指数评分≥15)的参与者。
  • 参与者随机分配至先接受夜间皮下阿扑吗啡(最高5 mg/h)或匹配安慰剂,随机化采用计算机生成方案、区组大小为4、按中心分层。
  • 第一干预阶段后经历14晚洗脱期,再交叉至另一干预;每个治疗期包括10晚滴定阶段和7晚固定剂量阶段。
  • 共纳入46例参与者,25例(54%)先接受阿扑吗啡,21例(46%)先接受安慰剂;分析基于意向性治疗。

主要发现

  • PDSS评分平均变化在夜间阿扑吗啡输注组为15.18(SD 24.34),安慰剂组为5.23(21.52),治疗效应9.95(95%CI 0.88-19.03),p=0.041。
  • 阿扑吗啡期间25例(54%)参与者报告不良事件,安慰剂期间17例(37%)报告不良事件,p=0.16。
  • 阿扑吗啡组头晕发生率高于安慰剂组(7例[15%] vs 0例),p=0.041。

关键数值与推荐

  • 主要疗效终点为每个治疗期开始至结束时帕金森病睡眠量表(PDSS)评分的差异。
  • 失眠严重程度指数评分≥15定义为中重度失眠。
  • 阿扑吗啡给药剂量最高5 mg/h,滴定阶段根据每日电话评估睡眠质量和治疗耐受性调整剂量。

临床怎么用

  • 对于晚期帕金森病伴中重度失眠患者,夜间皮下阿扑吗啡输注可能有助于管理睡眠障碍(作者认为可能有用)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Insomnia is a frequent complaint of patients with Parkinson's disease, and it negatively affects quality of life. Drugs that improve both sleep and parkinsonism would be of major benefit to patients with Parkinson's disease-related insomnia. We aimed to test the safety and efficacy of subcutaneous night-time only apomorphine infusion in patients with Parkinson's disease and insomnia. METHODS: We did a randomised, multicentre, double-blind, placebo-controlled, crossover trial in 11 expert centres in Parkinson's disease and sleep centres in France. Participants aged 35-90 years with fluctuating Parkinson's disease and moderate to severe insomnia (Insomnia Severity Index score ≥15) were randomly assigned to either first receive night-time subcutaneous apomorphine (up to 5 mg/h) or matching placebo. Randomisation was done using a computer-generated plan in blocks of four, stratified by centre. This first intervention was followed by a 14-night washout period, then crossover to the other intervention. The treatment periods consisted of a 10-night titration phase followed by a 7-night fixed-dose phase. The dose was adjusted during the titration phase on the basis of a daily telephone call assessing sleep quality and treatment tolerability. The primary efficacy endpoint was the difference in Parkinson's disease sleep scale (PDSS) scores from the beginning to the end of each treatment period. Analysis was done on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, NCT02940912. FINDINGS: Between Jan 31, 2017, and Jan 29, 2021, 46 participants were enrolled. 25 (54%) patients were randomly assigned to receive apomorphine first and 21 (46%) patients to receive placebo first. Mean change in PDSS score was significantly greater with night-time apomorphine infusion (15·18 [SD 24·34]) compared with placebo (5·23 [21·52]; treatment effect 9·95 [95% CI 0·88-19·03]; p=0·041). Adverse events were reported in 25 (54%) participants during the apomorphine period and in 17 (37%) participants during the placebo period (p=0·16). Apomorphine was associated with more frequent dizziness than was placebo (seven [15%] vs 0; p=0·041). INTERPRETATION: Subcutaneous night-time only apomorphine infusion improved sleep disturbances according to difference on PDSS score, with an overall safety profile consistent with previous studies in Parkinson's disease. This treatment might be useful to manage sleep disturbances in patients with advanced Parkinson's disease and moderate to severe insomnia. FUNDING: Orkyn and Aguettant Pharma. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. De Cock VC, Dodet P, Leu-Semenescu S, et al. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol. 2022. PMID: 35429481. doi:10.1016/S1474-4422(22)00085-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。